Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm study of niraparib in Japanese patients with late-line HRD-positive high-grade serous ovarian cancer
jRCT2080224163Phase 2Completed
- Sponsor
- Takeda
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in ovarian cancer, High-grade serous carcinoma of the fallopian tube (HGSC) and primary peritoneal cancer (PPC), sponsored by Takeda. Started Nov 2018; status: completed.
02
Drugs
niraparib
03
Conditions
ovarian cancerHigh-grade serous carcinoma of the fallopian tube (HGSC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2080224163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224163.